Previous findings revealed that engagement of SGLT-1 by orally administered D-glucose protects the intestinal mucosa from lipopolysaccharides (LPS)-induced injury. Here, we tested whether engagement of SGLT-1 protected also from doxorubicin (DXR)/5-fluorouracil (5-FU)-induced and DSS-induced intestinal injuries using a new synthetic compound named BLF501 as SGLT-1 agonist. A large set of experiments was performed in order to assess damages induction and recovery after treatment with DXR/5-FU and DSS with or without co-treatment with BLF501 with particular attention for intestinal epithelial integrity. We evaluated the preservation of correct epithelial structure, correct formation and functionality of junctional systems, electrophisiological properties and physiological functionality of small and large intestine. In conclusion, oral administration of BLF501 greatly accelerated recovery from mucosal injury induced by DXR (alone or in combination with 5-FU) and DSS. These data suggest a novel therapeutic approach to reduce the severity of chemotherapy-induced mucositis and a new approach for IBDs treatment.

SGLT-1: A NEW THERAPEUTIC STRATEGY TO MAINTAINS INTESTINAL EPITHELIAL INTEGRITY AND BARRIER FUNCTION / D. Cardani ; tutor: C. Rumio ; coordinatore: L. Vizzotto. UNIVERSITA' DEGLI STUDI DI MILANO, 2013 Jan 18. 25. ciclo, Anno Accademico 2012. [10.13130/cardani-diego_phd2013-01-18].

SGLT-1: A NEW THERAPEUTIC STRATEGY TO MAINTAINS INTESTINAL EPITHELIAL INTEGRITY AND BARRIER FUNCTION

D. Cardani
2013

Abstract

Previous findings revealed that engagement of SGLT-1 by orally administered D-glucose protects the intestinal mucosa from lipopolysaccharides (LPS)-induced injury. Here, we tested whether engagement of SGLT-1 protected also from doxorubicin (DXR)/5-fluorouracil (5-FU)-induced and DSS-induced intestinal injuries using a new synthetic compound named BLF501 as SGLT-1 agonist. A large set of experiments was performed in order to assess damages induction and recovery after treatment with DXR/5-FU and DSS with or without co-treatment with BLF501 with particular attention for intestinal epithelial integrity. We evaluated the preservation of correct epithelial structure, correct formation and functionality of junctional systems, electrophisiological properties and physiological functionality of small and large intestine. In conclusion, oral administration of BLF501 greatly accelerated recovery from mucosal injury induced by DXR (alone or in combination with 5-FU) and DSS. These data suggest a novel therapeutic approach to reduce the severity of chemotherapy-induced mucositis and a new approach for IBDs treatment.
18-gen-2013
Settore BIO/16 - Anatomia Umana
SGLT-1 ; chemotherapy induced mucositis ; inflammatory bowel diseases ; D-glucose synthetic analogues
RUMIO, CRISTIANO
VIZZOTTO, LAURA
Doctoral Thesis
SGLT-1: A NEW THERAPEUTIC STRATEGY TO MAINTAINS INTESTINAL EPITHELIAL INTEGRITY AND BARRIER FUNCTION / D. Cardani ; tutor: C. Rumio ; coordinatore: L. Vizzotto. UNIVERSITA' DEGLI STUDI DI MILANO, 2013 Jan 18. 25. ciclo, Anno Accademico 2012. [10.13130/cardani-diego_phd2013-01-18].
File in questo prodotto:
File Dimensione Formato  
phd_unimi_R08679.pdf

accesso aperto

Tipologia: Tesi di dottorato completa
Dimensione 4.15 MB
Formato Adobe PDF
4.15 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/215121
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact